235 related articles for article (PubMed ID: 20233623)
1. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
Emley A; Yang S; Wajapeyee N; Green MR; Mahalingam M
J Cutan Pathol; 2010 Mar; 37(3):344-9. PubMed ID: 19788444
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
Nguyen LP; Emley A; Wajapeyee N; Green MR; Mahalingam M
Br J Dermatol; 2010 Mar; 162(3):677-80. PubMed ID: 19919630
[TBL] [Abstract][Full Text] [Related]
4. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.
Wajapeyee N; Serra RW; Zhu X; Mahalingam M; Green MR
Cell; 2008 Feb; 132(3):363-74. PubMed ID: 18267069
[TBL] [Abstract][Full Text] [Related]
6. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
Wu J; Rosenbaum E; Begum S; Westra WH
Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
[TBL] [Abstract][Full Text] [Related]
7. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi.
Park E; Yang S; Emley A; DeCarlo K; Richards J; Mahalingam M
Am J Dermatopathol; 2012 Feb; 34(1):41-6. PubMed ID: 22094233
[TBL] [Abstract][Full Text] [Related]
9. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
Sigg C; Pelloni F; Schnyder UW
Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
11. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
12. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
Kanitakis J; Baldassini S; Lora V; Euvrard S
Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
[TBL] [Abstract][Full Text] [Related]
14. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
Dyduch G; Okoń K; Pescarini E
Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
[TBL] [Abstract][Full Text] [Related]
15. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
17. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
[TBL] [Abstract][Full Text] [Related]
18. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
Wong RP; Khosravi S; Martinka M; Li G
Oncol Rep; 2008 Apr; 19(4):933-7. PubMed ID: 18357378
[TBL] [Abstract][Full Text] [Related]
19. IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Scurr LL; Pupo GM; Becker TM; Lai K; Schrama D; Haferkamp S; Irvine M; Scolyer RA; Mann GJ; Becker JC; Kefford RF; Rizos H
Cell; 2010 May; 141(4):717-27. PubMed ID: 20478260
[TBL] [Abstract][Full Text] [Related]
20. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]